Effectiveness of polypill for primary and secondary prevention of cardiovascular disease: a pragmatic cluster-randomised controlled trial (PolyPars)
Authors' conclusion
The fixed-dose combination therapy using polypill can safely halve the risk of major cardiovascular diseases at the population level.
Study context
- Population
- Residents aged 50–75 years in a rural district of southern Iran (91 villages)
- Participants
- 4,415 residents91 villages
- Comparison
- Polypill plus non-pharmacological intervention vs non-pharmacological intervention alone
- Polypilln = 2,200
- Controln = 2,215reference
- Primary endpoint
- First major CV event: hospitalisation for ACS (non-fatal MI, unstable angina), fatal MI, non-fatal and fatal stroke, sudden death and HF
- Follow-up
- Median 4.6 years
Methodological detailspragmatic, two-arm, nested within the PARS cohort study, Adherence to polypill 86%
- Pragmatic
- Two-arm
- Nested within the PARS cohort study
- Adherence to polypill 86%
Primary result
As reported in the abstract
Safety
Serious adverse events
- No difference between the two groups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effectiveness of polypill for primary and secondary prevention of cardiovascular disease: a pragmatic cluster-randomised controlled trial (PolyPars). Heart. Published 14 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →